Af­ter at­tract­ing mul­ti­ple Chi­nese phar­ma part­ners, XtalPi grabs an­oth­er $400M to re­fine AI for drug dis­cov­ery

Build­ing the kind of ar­ti­fi­cial in­tel­li­gence in­fra­struc­ture re­quired to make a dent in drug dis­cov­ery takes re­al mon­ey — mon­ey that in­vestors have been hap­py to lav­ish. Big play­ers, or emerg­ing ones flush with cash, are now pop­ping up on the map in every di­rec­tion you look: Ex­sci­en­tia in Ox­ford, UK; Daphne Koller’s in­sitro in San Fran­cis­co; Re­cur­sion in Utah; Deep Ge­nomics in Toron­to; and In­sil­i­co in Hong Kong.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER